The Canadian hepatitis C treatment landscape: Time to turn chaos into order [0.03%]
加拿大丙肝治疗现状：是时候化混乱为有序了
Kienan P Williams,Kate Pr Dunn,Samuel S Lee
Kienan P Williams
Annual trends of hepatitis C virus infection in Manitoba between 1998 and 2018: A focus on special populations [0.03%]
1998至2018年马尼托巴省丙型肝炎病毒感染的年度趋势：重点关注特殊人群
Sai Krishna Gudi,Sherif Eltonsy,Joseph Delaney et al.
Sai Krishna Gudi et al.
Background: Hepatitis C virus (HCV) infection is a major cause of liver-related morbidity and mortality worldwide. Epidemiological data of HCV infection in the Canadian province of Manitoba are limited. ...
Province-to-province variability in hepatitis C testing, care, and treatment across Canada [0.03%]
加拿大各省丙型肝炎检测、治疗和照护的差异性分析
Erin Mandel,Kate Underwood,Chelsea Masterman et al.
Erin Mandel et al.
Background: Few countries have implemented the necessary policy changes to reduce the number of steps in the cascade of care to achieve hepatitis C virus (HCV) elimination, including Canada. The aim of this study was to d...
Stephen E Congly,Vladimir Marquez,Rahima A Bhanji et al.
Stephen E Congly et al.
Background: Exception points for liver transplant (LT) allocation are used to account for mortality risk not reflected by scoring systems such as the Model for End-Stage Liver Disease with sodium (MELD-Na). Currently, the...
Impact of decompensated cirrhosis in children: A population-based study [0.03%]
儿童失代偿期肝硬化的流行病学特征及预后：基于人群的队列研究
Mohit Kehar,Rebecca Griffiths,Jennifer A Flemming
Mohit Kehar
Background: We describe the proportion of children with compensated cirrhosis who develop decompensation in Ontario, Canada over the past two decades. Met...
Review of liver transplantation candidacy and outcomes among patients who use cannabis: Is it time for a change in policy? [0.03%]
评估大麻使用者肝移植资格和结局：是时候改变政策了吗？
Man Ting Kristina Yau,Trana Hussaini,Eric M Yoshida
Man Ting Kristina Yau
Background: Recreational cannabis was legalized in Canada in 2018. A controversial contraindication for liver transplantation is cannabis. There is currently no consensus regarding cannabis use in liver transplant candida...
Priority actions for elevating liver health in Canada: A call to action [0.03%]
提升加拿大肝脏健康的优先行动：呼吁采取行动
Mayur Brahmania,Mia J Biondi,Supriya Joshi et al.
Mayur Brahmania et al.
Chronic liver disease (CLD) has become a silent epidemic in our country and has resulted in significant physical, psychosocial, and financial burden. Although other international liver associations have published frameworks for the principa...
Albuminuria post-liver transplant is a predictor of kidney disease progression and mortality [0.03%]
肝移植后的蛋白尿会加重肾脏疾病并导致死亡率升高
Julie Anne Ting,Dilshani Induruwage,Eric M Yoshida et al.
Julie Anne Ting et al.
BACKGROUND: Albuminuria is a marker of chronic kidney disease (CKD) associated with an increased risk of end-stage kidney disease (ESKD) and mortality in the general population, but it is uncertain whether the same association exists in liv...
Disparities in health utilities among hepatitis C patients receiving care in different settings [0.03%]
不同医疗环境下接受治疗的丙型肝炎患者之间的健康效用差异
Yasmin A Saeed,Kate Mason,Nicholas Mitsakakis et al.
Yasmin A Saeed et al.
BACKGROUND: Although chronic hepatitis C (CHC) disproportionately affects marginalized individuals, most health utility studies are conducted in hospital settings which are difficult for marginalized patients to access. We compared health u...
The 11th Canadian Symposium on Hepatitis C Virus: 'Getting back on track towards hepatitis C elimination' [0.03%]
第十一届加拿大丙型肝炎病毒研讨会：“重回丙型肝炎消除之路”
Ana Maria Passos-Castilho,Sasha Tejna Persaud Udhesister,Guillaume Fontaine et al.
Ana Maria Passos-Castilho et al.
Hepatitis C virus (HCV) affects approximately 204,000 Canadians. Safe and effective direct-acting antiviral therapies have contributed to decreased rates of chronic HCV infection and increased treatment uptake in Canada, but major challenge...